WO2013088371A3 - Use of the mmp-12 protein in the prevention and/or treatment of dandruff conditions of the scalp - Google Patents

Use of the mmp-12 protein in the prevention and/or treatment of dandruff conditions of the scalp Download PDF

Info

Publication number
WO2013088371A3
WO2013088371A3 PCT/IB2012/057242 IB2012057242W WO2013088371A3 WO 2013088371 A3 WO2013088371 A3 WO 2013088371A3 IB 2012057242 W IB2012057242 W IB 2012057242W WO 2013088371 A3 WO2013088371 A3 WO 2013088371A3
Authority
WO
WIPO (PCT)
Prior art keywords
scalp
mmp
polypeptide
seq
protein
Prior art date
Application number
PCT/IB2012/057242
Other languages
French (fr)
Other versions
WO2013088371A2 (en
Inventor
Audrey Gueniche
Isabelle Castiel
Original Assignee
L'oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L'oreal filed Critical L'oreal
Publication of WO2013088371A2 publication Critical patent/WO2013088371A2/en
Publication of WO2013088371A3 publication Critical patent/WO2013088371A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24065—Macrophage elastase (3.4.24.65), i.e. metalloelastase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

The present invention relates to the cosmetic use of an effective amount of at least one active agent consisting of a polypeptide having at least 80% amino acid identity with a metalloproteinase MMP-12 of sequence chosen from SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, or a C-terminal fragment of said polypeptide, for preventing and/or treating dandruff conditions of the scalp, said polypeptide or said fragment comprising the sequence KDXK, in which X represents aspartic acid or glutamic acid.
PCT/IB2012/057242 2011-12-14 2012-12-12 Use of the mmp-12 protein in the prevention and/or treatment of dandruff conditions of the scalp WO2013088371A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR1161621 2011-12-14
FR1161621A FR2984129B1 (en) 2011-12-14 2011-12-14 USE OF PROTEIN MMP-12 IN THE PREVENTION AND / OR TREATMENT OF FILM CONDITIONS OF SCALP
US201261603384P 2012-02-27 2012-02-27
US61/603,384 2012-02-27

Publications (2)

Publication Number Publication Date
WO2013088371A2 WO2013088371A2 (en) 2013-06-20
WO2013088371A3 true WO2013088371A3 (en) 2013-12-27

Family

ID=45926673

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/057242 WO2013088371A2 (en) 2011-12-14 2012-12-12 Use of the mmp-12 protein in the prevention and/or treatment of dandruff conditions of the scalp

Country Status (2)

Country Link
FR (1) FR2984129B1 (en)
WO (1) WO2013088371A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10660838B2 (en) 2017-06-23 2020-05-26 The Procter & Gamble Company Composition and method for improving the appearance of skin
US11622963B2 (en) 2018-07-03 2023-04-11 The Procter & Gamble Company Method of treating a skin condition
US11583488B2 (en) 2020-06-01 2023-02-21 The Procter & Gamble Company Method of improving penetration of a vitamin B3 compound into skin
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087325A2 (en) * 2002-04-08 2003-10-23 The Brigham And Women's Hospital, Inc. Methods and compositions for preventing and treating microbial infections
WO2009111083A2 (en) * 2008-03-06 2009-09-11 Halozyme, Inc. In vivo temporal control of activ at able matrix- degrading enzymes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10324567A1 (en) 2003-05-30 2004-12-23 Symrise Gmbh & Co. Kg Use of dihydroxyphenylmethane derivatives, e.g. styrylresorcinol, for control of microorganisms that cause dandruff, body odor, acne and mycoses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087325A2 (en) * 2002-04-08 2003-10-23 The Brigham And Women's Hospital, Inc. Methods and compositions for preventing and treating microbial infections
WO2009111083A2 (en) * 2008-03-06 2009-09-11 Halozyme, Inc. In vivo temporal control of activ at able matrix- degrading enzymes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RANGANATHAN, S. AND MUKHOPADHYAY, T.: "Dandruff: the most commercially exploited skin disease", INDIAN JOURNAL OF DERMATOLOGY, vol. 55, no. 2, June 2010 (2010-06-01), pages 130 - 134, XP002680785, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887514/?report=printable> [retrieved on 20120725], DOI: 10.4103/0019-5154.62734 *

Also Published As

Publication number Publication date
WO2013088371A2 (en) 2013-06-20
FR2984129A1 (en) 2013-06-21
FR2984129B1 (en) 2014-01-10

Similar Documents

Publication Publication Date Title
EP2532365A4 (en) Pharmaceutical composition for treatment and/or prevention of cancer
MX360208B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX363136B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX360211B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
NZ711037A (en) Peptides and compositions for treatment of joint damage
MX357505B (en) Medicinal composition for treating and/or preventing cancer.
EA201490809A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF NON-EFFECTIVE ERYTHROPOESIS
UA111141C2 (en) Recombinant antigen of rsv
NZ623576A (en) Tfpi inhibitors and methods of use
MX2012008998A (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX2012009000A (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX340016B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
SI2079481T1 (en) Vaccine peptide combinations against cat allergy
MY167232A (en) Polypeptides binding to human complement c5
WO2019045248A3 (en) Peptide exhibiting wrinkle-improving activity and uses thereof
NZ610389A (en) Use of a composition comprising an antimicrobial peptide as a food preservative
WO2013088371A3 (en) Use of the mmp-12 protein in the prevention and/or treatment of dandruff conditions of the scalp
NZ708091A (en) Stabilized insulin-like growth factor polypeptides
WO2007014253A3 (en) Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure
MX2017016227A (en) Broad-spectrum anti-infective peptides.
MX2018008545A (en) An antibacterial composition and a method of treating staphylococcal infections with the antibacterial composition.
PL394618A1 (en) Anticancer fusion protein
MX2018002616A (en) Fusion protein.
MX2017013480A (en) Pharmaceutical composition for treating and/or preventing cancer.
EA202090802A1 (en) PEPTIDE COMPOSITION FOR TREATMENT OF DAMAGE ASSOCIATED WITH EXCITING NEUROTOXICITY

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12815837

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12815837

Country of ref document: EP

Kind code of ref document: A2